DIAMYD™ DIABETES DRUG SHOWS EFFICACY IN A PHASE II TYPE 1-DIABETES TRIAL
Press Release, Stockholm, Sweden – August 22, 2006 – Diamyd Medical AB (SWEDEN OMXS: DIAM B; USA ADR: DMYDY)Diamyd Medical announces that its lead drug candidate, Diamyd™, has demonstrated overall statistically significant efficacy in preserving insulin production in a Phase II clinical trial in 70 children and adolescents with type 1-diabetes. No serious adverse events associated with the therapy were observed. The Principal Investigator found that the treatment is easy to give and that the study outcomes are of clinical importance for the treatment of type 1-diabetes. The Diamyd™ Phase